The BMJ Evidence Centre

BMJ 2008; 337 doi: http://dx.doi.org/10.1136/bmj.a2438 (Published 07 November 2008) Cite this as: BMJ 2008;337:a2438
  1. Charles Young, editor 1,
  2. Fiona Godlee, editor2
  1. 1BMJ Point of Care, BMJ Best Practice, and BMJ Clinical Evidence, London WC1H 9JR
  2. 2BMJ, London WC1H 9JR
  1. cyoung{at}bmjgroup.com

    A new, reactive, and innovative approach to healthcare information

    Michael Rawlins is right. In his Harveian Oration at the Royal College of Physicians last month he clearly signalled the medical profession’s overuse of randomised controlled trials to guide clinical decision making.1 Randomised controlled trials have had a long and influential relationship with the medical profession. Milestones in this relationship include James Lind and his controlled trial of lime juice for scurvy in 1747,2 and Bradford Hill’s trial of streptomycin for pulmonary tuberculosis in 19483; both trials championed this experimental approach to answering clinical questions. Perhaps Michael Rawlins will be similarly influential, but in the opposite direction—by emphasising the dangers of relying too much on randomised controlled trials almost to the exclusion of other types of useful information.

    Healthcare information, or evidence, varies in its source, quality, and usefulness. Information derived from research may be …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial